Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole

被引：0

作者：

C. Skedgel

D. Rayson

R. Dewar

T. Younis

机构：

[1] Dalhousie University,Department of Medicine, Centre for Clinical Research

[2] Cancer Care Nova Scotia,undefined

来源：

Breast Cancer Research and Treatment | 2007年 / 101卷

关键词：

Adjuvant hormonal therapy; Anastrozole; Aromatase inhibitors; Breast cancer; Cost-utility analysis; Exemestane; Tamoxifen;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：325 / 333

页数：8

共 50 条

[41] Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare perspective. The ATAC Trialists' Group.
Locker, GY
BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S105 - S105
[42] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
Karnon, Jonathan
Delea, Thomas
Barghout, Vicki
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2008, 9 (02): : 171 - 183
[43] Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective
Jonathan Karnon
Thomas Delea
Vicki Barghout
The European Journal of Health Economics, 2008, 9
[44] EFFECT OF TAMOXIFEN TREATMENT ON ESTROGEN METABOLISM IN POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER
LEVIN, J
MARKHAM, MJ
GREENWALD, ES
OCONNOR, JF
ZUMOFF, B
FUKUSHIMA, DK
ANTICANCER RESEARCH, 1982, 2 (06) : 377 - 379
[45] TAMOXIFEN VERSUS ETHINYL ESTRADIOL IN THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER
BEEX, L
PIETERS, G
SMALS, A
KOENDERS, A
BENRAAD, T
KLOPPENBORG, P
CANCER TREATMENT REPORTS, 1981, 65 (3-4): : 179 - 185
[46] The effect of anastrozole, tamoxifen or a combination of both drugs on mammographic breast density in post menopausal women with breast cancer.
Cuzick, J.
Warren, R.
Pinney, L.
Warwick, J.
Howell, A.
BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S224 - S224
[47] THERAPEUTIC EFFECT OF TAMOXIFEN VERSUS TAMOXIFEN COMBINED WITH MEDROXYPROGESTERONE ACETATE IN ADVANCED BREAST-CANCER IN POST-MENOPAUSAL WOMEN
MOURIDSEN, HT
ELLEMANN, K
MATTSSON, W
PALSHOF, T
DAEHNFELDT, JL
ROSE, C
CANCER TREATMENT REPORTS, 1979, 63 (02): : 171 - 175
[48] Cognitive function - A longitudinal study of the effects of anastrozole on cognition in post-menopausal women at risk of developing breast cancer
Atkins, L
Jenkins, V
Fallowfield, LJ
Howell, A
PSYCHO-ONCOLOGY, 2004, 13 (08) : S21 - S21
[49] Comparison of the cost-effectiveness of letrozole or anastrozole versus tamoxifen as adjuvant therapies for early breast cancer in hormone receptor positive (HR+) postmenopausal women: The UK perspective
Karnon, Jonathan
Delea, Thomas
Papo, Natalie L.
Barghout, Victoria
ANNALS OF ONCOLOGY, 2006, 17 : 107 - 107
[50] A randomized, phase III trial exploring the effects of neoadjuvant sequential treatment with steroidal (exemestane) and non-steroidal (anastrozole) aromatase inhibitors on biomarkers in post-menopausal women with hormone receptor positive locally advanced breast cancer (LABC)
Freedman, O.
Amir, E.
Dranitsaris, G.
Dowsett, M.
Cole, D. E. C.
Hanna, W.
O'Malley, F.
Folkerd, E.
Verma, S.
Clemons, M. J.
EJC SUPPLEMENTS, 2009, 7 (02): : 269 - 269

← 1 2 3 4 5 →